Home > News > 34/Feasibility study of using a diamond tip temperature-controlled radiofrequency ablation system for ischaemic cardiomyopathy (ICM) ventricular tachycardia (VT) ablation
Arrhythmia
Read Time: 2 mins

34/Feasibility study of using a diamond tip temperature-controlled radiofrequency ablation system for ischaemic cardiomyopathy (ICM) ventricular tachycardia (VT) ablation

Published Online: October 3rd 2021 European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr34
Authors: J Al-Sheikhli (Presenting Author) - University Hospital Coventry and Warwickshire, Coventry; I Patchett - University Hospital Coventry and Warwickshire, Coventry; V Lim - University Hospital Coventry and Warwickshire, Coventry; L Marshall - University Hospital Coventry and Warwickshire, Coventry; S Yusuf - University Hospital Coventry and Warwickshire, Coventry; S Panikker - University Hospital Coventry and Warwickshire, Coventry; W Foster - University Hospital Coventry and Warwickshire, Coventry; M Kuehl - University Hospital Coventry and Warwickshire, Coventry; F Osman - University Hospital Coventry and Warwickshire, Coventry; T Dhanjal - University Hospital Coventry and Warwickshire, Coventry
Quick Links:
Article
Article Information
Article:

Introduction: The DiamondTemp ablation (DTA) catheter system delivers high-power, open-irrigated, temperature-controlled radiofrequency (RF) ablation. This study assesses the feasibility of this new technology for VT ablation in patients with ICM.

Method: 10 patients (mean age 73.4 years [64–84 years]) with a diagnosis of ICM were recruited over 3 months. 4 patients were classified as high risk and 6 as intermediate risk using the PAINESD score. All patients were on optimal anti-arrhythmic drug therapy: B-blocker (n=10), amiodarone (n=7), mexiletine (n=3). The Ensite Precision Cardiac Mapping System was used to construct substrate maps with the Advisor HD Grid mapping catheter with an average point density of 2,344/26,165 (points used/points collected). Ablation lesions were delivered as per standard protocol: Temperature set to 60°C for an empirical lesion duration of 60 s, or shorter if i) failure to achieve a temperature of 45°C, ii) impedance drop of 15 Ω reached or iii) rising impedance. Metrics recorded during the ablation included time, power, impedance, and temperature, were collected at a rate of 1 Hz. Mapping was performed as per the UHCW VT mapping and ablation workflow with analysis of pre- and post-ablation bipolar and unipolar total scar area (TSA), border-zone area (BZA), dense scar area (DSA), late potential area (LPA), mean bipolar and unipolar voltages of ablation target areas (ATA). Standard VT induction protocols was performed at the end of each procedure.

Results: Average number of lesions per case was 51.8 ± 17.7, average time per lesion was 44.5 ± 11.1 s, average power per case was 47.8 ± 1.2 W, average temperature per case was 49.8 ± 2 °C, average maximum temperature per lesion was 55.2 ± 2 °C at an average duration of 25.8 ± 8 s and the average impedance drop per lesion was 11.2 ± 2.4 Ω at an average duration of 23.0 ± 7 s. Map data analysis is displayed in Table 1. There was a significant reduction in the average BZA of 4.4 cm2 or 12% (p=0.026) and LPA of 3.5 cm2 (p=0.0449). There was a significant reduction in the mean bipolar voltage of ATA, 0.14 mV (p=0.0007) and mean unipolar voltage of ATA, 0.59 mV (p=0.0072). There was no inducible clinical or non-clinical VT at the end of 9 procedures, with no stimulation performed at the end of 1 case due to pericardial tamponade requiring drainage.

Conclusion and implications: The DTA catheter system resulted in a significant reduction of both mean bipolar and unipolar voltages of the ATA. The average bipolar BZAs and LPAs were significantly reduced with no inducible clinical or non-clinical VT at the end of the tested procedures. This is the first study to report the efficacy and safety of the DTA catheter system in VT ablation, which positively impacts on key substrate ablation targets with consistent on-table endpoint testing outcomes. Further studies investigating both long-term clinical outcomes and performance to comparable ablation technology is required.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
Arrhythmia
43/Cardiac tamponade as a complication of transseptal puncture: associations and operatordependent variables during left atrial ablation at Barts Heart Centre
E Maclean (Presenting Author) - St Bartholomew’s Hospital, London; K Mahtani - St Bartholomew’s Hospital, London; C Butcher - St Bartholomew’s Hospital, London; N Ahluwalia - St Bartholomew’s Hospital, London; M Finlay - St Bartholomew’s Hospital, London; S Honarbakhsh - St Bartholomew’s Hospital, London; A Creta - St Bartholomew’s Hospital, London; A Chow - St Bartholomew’s Hospital, London; V Sawhney - St Bartholomew’s Hospital, London; V Ezzat - St Bartholomew’s Hospital, London; MJ Earley - St Bartholomew’s Hospital, London; M Dhinoja - St Bartholomew’s Hospital, London; S Sporton - St Bartholomew’s Hospital, London; MD Lowe - St Bartholomew’s Hospital, London; PD Lambiase - St Bartholomew’s Hospital, London; F Khan - St Bartholomew’s Hospital, London; SY Ahsan - St Bartholomew’s Hospital, London; RJ Hunter - St Bartholomew’s Hospital, London; RJ Schilling - St Bartholomew’s Hospital, London; O Sega - St Bartholomew’s Hospital, London Read Time: 2 mins

European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr43

Introduction: Cardiac tamponade is a high morbidity complication of transseptal puncture (TSP). We examined the incidence and predictors of TSP-related cardiac tamponade (TRCT) for all patients undergoing left atrial ablation at our centre from 2016-2020. Methods: Patient and procedural variables were extracted retrospectively. Cases of cardiac tamponade were scrutinised to adjudicate TSP culpability. Adjusted multivariate […]

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72